Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity ...

Firm Novo Nordisk’s global patent is set to expire in parts of the world from early 2026, allowing cut-price ‘own-label’ ...

Higher doses of weight loss medications like Ozempic and Wegovy could help treat obesity. In two new studies, people taking 7 ...

Dr Saptarshi Bhattacharya shared how weight loss injections can help you keep off the weight – but are they actually safe? Here's everything you need to know.

Trial participants who received an increased weekly dose of Wegovy lost 19 per cent of their body weight in a year on average ...

Despite its dramatic ability to cut pounds by curbing appetite, high costs, unpleasant side effects, and health complications ...

Semaglutide (better known as Wegovy) may help people with obesity lose up to 25% of their body weight when used at a higher ...

Semaglutide is currently administered through a weekly dose of up to 2.4 milligrams injected into the layer of fat over the ...

Pharmaceutical companies are racing to develop a GLP-1 weight-loss drug in pill form. Novo Nordisk says its oral semaglutide ...

Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily ...

Novo’s (NVO) semaglutide and Lilly’s (NYSE:LLY) tirzepatide are recommended in Europe as first-line obesity treatments. Read more here.

Medically reviewed by Femi Aremu, PharmD Key Takeaways While both contain semaglutide, Wegovy is approved specifically for weight management, whereas Ozempic is approved for the treatment of type 2 ...